{"id":"menveo-menactra","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Pain at injection site","drugRate":"60-80%","severity":"Mild to moderate"},{"effect":"Redness at injection site","drugRate":"20-30%","severity":"Mild"},{"effect":"Swelling at injection site","drugRate":"10-20%","severity":"Mild"},{"effect":"Headache","drugRate":"20-30%","severity":"Mild to moderate"},{"effect":"Fatigue","drugRate":"10-20%","severity":"Mild"},{"effect":"Myalgia","drugRate":"10-20%","severity":"Mild"},{"effect":"Fever","drugRate":"10-20%","severity":"Mild"}],"contraindications":["Severe allergic reaction (e.g., anaphylaxis) to a previous dose of the vaccine or any component of the vaccine"],"specialPopulations":{"Geriatric":"Efficacy and safety in adults over 55 years of age may differ from younger adults.","Lactation":"Safety in lactating women has not been established.","Pediatric":"Approved for use in individuals aged 2 months and older.","Pregnancy":"Not recommended during pregnancy unless the benefits outweigh the risks."}},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2005","type":"Approval","milestone":"FDA approval of Menactra®","regulator":"FDA"},{"date":"2010","type":"Approval","milestone":"FDA approval of Menveo®","regulator":"FDA"}],"_dailymed":null,"aiSummary":"Menveo/Menactra is a vaccine antigen that targets Neisseria meningitidis serogroups A, C, Y, and W. It is a conjugate vaccine that uses oligosaccharides from the bacteria, conjugated to Corynebacterium diphtheriae CRM197, to stimulate an immune response.","ecosystem":[],"mechanism":{"target":"Neisseria meningitidis serogroups A, C, W, and Y","novelty":"Menveo® and Menactra® were among the first conjugate vaccines to protect against multiple serogroups of Neisseria meningitidis.","modality":"Prophylactic","drugClass":"Conjugate vaccine","explanation":"These vaccines contain polysaccharide antigens from the bacterial capsule of Neisseria meningitidis, which are conjugated to a carrier protein to enhance immunogenicity.","oneSentence":"Menveo® and Menactra® are conjugate vaccines that stimulate the immune system to produce antibodies against Neisseria meningitidis serogroups A, C, W, and Y.","technicalDetail":"The conjugation process involves linking the polysaccharide antigens to a protein carrier, such as diphtheria toxoid or CRM197, to improve T-cell-dependent immune responses and provide long-lasting protection."},"_scrapedAt":"2026-03-27T23:54:26.766Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"Not available","launchDate":"Menveo®: 2010, Menactra®: 2005","annualCostUS":"Not available","currentRevenue":"Not available","patientPopulation":"Individuals aged 2 months and older at risk of meningococcal disease","peakSalesEstimate":"Not available"},"references":[],"biosimilars":[],"competitors":["Bexsero® (Novartis)","Trumenba® (Pfizer)"],"indications":{"approved":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06128733","phase":"PHASE1, PHASE2","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-10-31","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1215},{"nctId":"NCT06436274","phase":"PHASE4","title":"Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-14","conditions":"Human Papilloma Virus, Hiv","enrollment":778},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT02199691","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-07-22","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1715},{"nctId":"NCT03077438","phase":"PHASE3","title":"Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-17","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1000},{"nctId":"NCT04875819","phase":"PHASE4","title":"Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","status":"RECRUITING","sponsor":"Thomas Benfield","startDate":"2021-04-28","conditions":"Hiv, Meningococcal Infections, Pneumococcal Infections","enrollment":55},{"nctId":"NCT03682939","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2019-02-21","conditions":"Hiv, Meningitis, Meningococcal, HIV Infections","enrollment":55},{"nctId":"NCT02106390","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-05","conditions":"Infections, Meningococcal","enrollment":750},{"nctId":"NCT02072525","phase":"PHASE4","title":"A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-01","conditions":"Meningococcal","enrollment":359},{"nctId":"NCT02097849","phase":"PHASE2","title":"Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-02-28","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":71},{"nctId":"NCT01782066","phase":"PHASE1, PHASE2","title":"Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2013-01","conditions":"Meningococcal Disease","enrollment":12},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":70,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Menveo®/Menactra®","genericName":"Menveo®/Menactra®","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Biologic","firstApprovalDate":"Menveo®: 2010, Menactra®: 2005","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}